The changing attitude of European VCs

Article Abstract:

The findings of a new survey conducted by academics from Bocconi University (Milan), Stanford University's graduate school of business (Stanford, CA, USA) and the European Investment Fund (Luxembourg), indicate that risk averse venture capitalists (VCs), who are backed by banks and are reluctant to invest during the initial stages, are dominating the European biotech and medical sectors. New VCs who are willing to take risks with seed financing are now making their presence felt.

United States, Europe, Financial management, Venture Capital Companies, Miscellaneous Intermediation, Investors, not elsewhere classified, Biotechnology industry, Biotechnology industries, Company investment, Investments

---

Next-generation monoclonals less profitable than trailblazers?

Article Abstract:

A study completed in June 2005 by London-based consultancy Propagate Pharma states that therapeutics based on monoclonal antibodies (mAbs) are far more likely to be commercially successful than their small-molecule predecessors. The next generation of mAb-involved biotech companies may not find it easy to sustain the trend as competition among the new crop of mAbs and from other types of biological products is likely to intensify.

United Kingdom, Science & research, Biological Product (except Diagnostic) Manufacturing, Biological Products, Research, Monoclonal antibodies, Materials

---

Similar abstracts:

• Abstracts: The United States of South America? Latin America casts its gaze to the east
• Abstracts: Making the jump to must-have. Revenue recognition moves up on corporate agendas. 8th annual Alexander Hamilton Award winners
• Abstracts: The impact of cause branding on consumer reactions to products: does products / cause efitE really matter?. The 'Value of Marketing' and 'The Marketing Of Value" in contemporary times- A literature review and research agenda
• Abstracts: The future of video. Pool tables from around the globe. Sega to outrun the opposition
• Abstracts: Gaining confidence in high-throughput protein interaction networks . Closing the circle of osmoregulation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.